Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.52
-0.66 (-2.62%)
At close: Apr 16, 2026, 4:00 PM EDT
24.48
-0.04 (-0.16%)
After-hours: Apr 16, 2026, 5:18 PM EDT
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,371 employees as of December 31, 2025. The number of employees increased by 77 or 5.95% compared to the previous year.
Employees
1,371
Change (1Y)
77
Growth (1Y)
5.95%
Revenue / Employee
$490,883
Profits / Employee
-$419,402
Market Cap
2.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,371 | 77 | 5.95% |
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ascentage Pharma Group International | 767 |
| ADMA Biologics | 647 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
| Kodiak Sciences | 124 |
| Definium Therapeutics | 106 |
RARE News
- 13 days ago - DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026 - PRNewsWire
- 17 days ago - Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - GlobeNewsWire
- 22 days ago - Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewsWire
- 27 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Benzinga
- 5 weeks ago - Ultragenyx's gene therapy helps control ammonia levels in late-stage study - Reuters
- 7 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights - Newsfile Corp
- 7 weeks ago - Ultragenyx to Participate at Investor Conferences in March - GlobeNewsWire